Running Title: Myeloid Derived Suppressor Cells in Diseases

Myeloid Derived Suppressor Cells and Their Role in Diseases

Y.Y. Kong[1], M. Fuchsberger[1], S.D. Xiang*[,1], V. Apostolopoulos*[,2] and M. Plebanski*[,1]

[1] Department of Immunology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Alfred Hospital Campus, 88-89 Commercial Rd, Melbourne, Vic 3004. Australia

[2] VA Consulting Services, Melbourne, Vic 3030, Australia

* Corresponding authors: Prof. Magdalena Plebanski, Prof. Vasso Apostolopoulos and Dr. Sue D. Xiang Department of Immunology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Alfred Hospital Campus, 88-89 Commercial Rd, Melbourne, Vic 3004. Australia; Tel: 61 3 9903 0627; Emails: Magdalena.Plebanski@monash.edu; vasso@scientist.com; Sue.Xiang@monash.edu

Abstract:

Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of myeloid progenitors that can play a major role in tumour development and chronic inflammation. The importance of the suppressive function of MDSCs was first suggested by studies involving cancer patients and cancer-bearing mice. In addition, recent studies have demonstrated that MDSCs can also be involved in many other pathological conditions. MDSCs have unique ways of abrogating an immune response in addition to those utilised by other immune-suppressive cell types, for example via the induction of arginase-1 and consequent upregulation in reactive oxygen species (ROS) production. Due to their heterogeneity, they further can express a variety of lineage markers, which overlap with other myeloid cell types such as Gr1, CD11b, MHCII^{lo}, Ly6C and Ly6G, making it difficult to identify them by surface phenotype alone. The disparity between mouse and human MDSCs further complicates the identification of these elusive cell populations. In this review, we will summarise the recent updates on the methods for eliciting and studying different MDSC subsets, including newly proposed surface phenotypes, as well as insights into how their function is being characterised in both mice and humans. In addition, exciting new discoveries suggesting their involvement across a number of different pathological settings, such as sepsis, autoimmunity and *Leishmaniasis*, will be discussed.

List of abbreviations:

Myeloid derived suppressor cells, MDSCs; dendritic cells, DCs; inducible nitric oxide synthase, iNOS; reactive oxygen species, ROS; major histocompatibility complex class II, MHCII; monocytic MDSCs, Mo-MDSCs; granulocytic MDSCs, G-MDSCs; transforming growth factor-β, TGF-β; interferon-γ, IFN-γ; granulocyte/ macrophage colony stimulating factor, GM-CSF; vascular endothelial growth factor, VEGF; prostaglandin E$_2$, PGE$_2$; natural killer, NK; regulatory T-cells, T-regs; hematopoietic stem cells, HSCs; nitric oxide, NO; janus-kinase, JAK; signal transducer and activator of transcription, STAT; antigen-presenting cells, APCs; hepatitis C virus, HCV; hemagglutinin, HA; S100 calcium binding protein A8 and 9, S100A8 and S100A9; inflammatory bowel diseases, IBD

1. INTRODUCTION

Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of early myeloid progenitors, which includes immature granulocytes, macrophages, and dendritic cells (DCs) [1-3]. MDSCs are often generated and expanded and acquire their suppressive abilities during pathological conditions such as traumatic injuries, tumour development and pathogenic infections [4-8].

MDSCs can play a major role in tumour development and chronic inflammation due to their potent regulatory roles in immune responses [9-11]. For example, upon activation by tumour-derived mediators or host-induced cytokines, these cells express immunosuppressive factors such as arginase-1, inducible nitric oxide synthase (iNOS) or reactive oxygen species (ROS), which can initiate programmed cell death and apoptosis in T cells and other effector cells [12, 13]. In this review, we will summarise the recent updates on diverse phenotypes and functions of MDSCs, as well as new insights recently gained into their involvement in different pathological settings.

2. ORIGIN AND SUBSETS OF MDSCs

At normal steady-state conditions, MDSCs are commonly found in naïve mouse bone marrow (20-30%), and are scarce in the spleen (2-4%), blood (2-4%), pancreas (1-2%), liver (2-5%) and lymph nodes (<1%) [14, 15]. As a heterogeneous population of cells, MDSCs can often express a variety of markers, which overlap with other myeloid lineage cells such as dendritic cells (DCs), granulocytes and monocytes (Figure 1) [1-3]. Although MDSCs are not a defined subset of cells, in mice they are characterised by the co-expression of myeloid lineage differentiation antigen Gr-1, myeloid cell marker, CD11b and low levels of major histocompatibility complex class II (MHCII), which are expressed on antigen-presenting cells to present antigens and activate the adaptive immunity [16] (Table 1).

Gr-1 is expressed on mature granulocytes in bone marrow and peripheral tissues and also transiently on monocytes during their differentiation in the bone marrow. Furthermore, it is an epitope expressed on Ly6C (monocytic/macrophage marker) and Ly6G (granulocytic/neutrophil marker). Studies have shown that MDSCs can be further divided into two different subsets based on the expression of Ly6C and Ly6G molecules [17]. Cells that have a monocytic MDSC phenotype express CD11b, high levels of Ly6C but no Ly6G. They are less granular (low side-scatter when assessed by flow cytometry) and express higher levels of monocytic markers such as F4/80, ICAM-1, and CCR2 when compared to the granulocytic subset of MDSCs [1, 18, 19]. Monocytic MDSCs (Mo-MDSCs), characterised as CD11b$^+$Ly6C^{hi}Ly6G$^-$ cells express arginase-1 and exert their suppression on antigen-specific CD8$^+$ T-cell activation via a NOS-mediated mechanism [19]. Granulocytic MDSCs (G-MDSCs) are described as CD11b$^+$Ly6C$^{lo/int}$Ly6G^{hi} and are more granular (high side-scatter when assessed by flow cytometry) when compared to Mo-MDSCs [19]. These cells also express high levels of arginase-1, but unlike Mo-MDSCs, they mediate suppression of CD8$^+$ T-cell activation and proliferation via a ROS-mediated mechanism [17]. Although both subsets of MDSCs initiate suppression of CD8$^+$ T-cell activity via different mechanisms, both populations generally express CD115 (M-CSF receptor), CD16/32 (Fc receptor), CD124 (IL-4 receptor) and low levels of CD80 [20-22]. However, these molecules appear not to be involved in the immunosuppressive roles of MDSCs [17].

Fig. (1). Comparison of marker expression on dendritic cells and MDSCs

		Phenotype		Functional Markers		Functional Proteins	
Mouse	Mo-MDSCs	CD11b+ CD16+ CD31+ CD115+/- CD120blo CD124+/-	SSClo CD49dhi F4/80+ Ly6C+ Ly6G-	CD40+ CD80+ MHCII-/lo		S100A8+ S100A9+ Arginase-1 IL-10	iNOS
	G-MDSCs		SSChi CD49dlo F4/80- Ly6Clo/int Ly6G+		CCR2+ ICAM-1+		ROS
Human	Mo-MDSCs	CD11b+ CD66hi CD124+ CD125+ VEGFR+	SSClo CD14+ CD15- CD33hi	CD40- CD80- CD83- HLA DR-/lo		S100A9+ Arginase-1	iNOS Il-10 IL-13 TGFβ
	G-MDSCs		SSChi CD14- CD15+ CD33int				ROS

Table 1. Phenotypic and functional markers of murine and human MDSCs.

Unlike murine MDSCs, human MDSCs are often identified as lineage$^-$ CD11b$^+$ HLA DR$^{-/lo}$ [23, 24]. Several recent studies have shown that subsequent characterisation of human MDSC subsets can be done with the expression of CD14 and CD15 molecules [25-28]. Identification of a CD11b$^+$ CD14$^-$ CD15$^+$ population with granulocyte morphology in renal cell carcinoma patients has been described as the human equivalent to G-MDSCs in mice [29] (Table 1). These cells have been shown to be a subpopulation of activated granulocytic cells expressing high levels of CD66b and VEGFR1. They have low to no expression of classic activation markers such as CD80, CD83, CD86 and MHCII, but are capable to secrete high levels of arginase-1, which can be released through degranulation of intracellular granules upon activation [29, 30]. Depletion of CD11b$^+$ cells and not CD14$^+$ cells has shown to re-establish T-cell proliferation, cytokine secretion and expression of CD3ζ chain, suggesting that G-MDSCs are the main source of arginase-1 secretion in these patients [29]. Human Mo-MDSCs on the other hand can be identified as CD11b$^+$ CD14$^+$ HDR$^{-/lo}$ in melanoma patients [27, 31]. These cells promote immunosuppression by spontaneously expressing transforming growth factor-ß (TGF-ß) [31]. Depletion of CD14$^+$ cells restores T-cell proliferation and interferon-γ (IFN-γ) secretion. Although it is generally agreed that murine MDSCs are identified as CD11b$^+$ Gr-1$^+$ cells, and various studies have attempted to investigate human MDSCs with various combinations of lineage markers [32-36], until a definitive marker is found, the phenotypic definition of MDSCs will remain ambiguous.

3. GENERATION AND ACTIVATION OF MURINE MDSCs

Murine MDSCs can be generated in *in vitro* cultures from bone marrow cells using granulocyte/macrophage colony stimulating factor (GM-CSF). Depending on the concentration of GM-CSF, MDSCs can be generated between 3-10 days [3]. Higher concentration of GM-CSF leads to a more rapid development of MDSCs within the culture, but will also generate neutrophils. In contrast, at lower concentrations of GM-CSF in culture MDSCs can be generated within 8-10 days. However, DCs are generated simultaneously in those cultures [37]. GM-CSF can be secreted at a high concentration by T-cells, DCs and natural killer (NK) cells in the presence of an immune response [38-40] leading to an accumulation of MDSCs within the site of inflammation.

In addition to GM-CSF, several soluble factors such as granulocyte colony-stimulating factor (G-CSF) [41], macrophage colony-stimulating factor (M-CSF) [42], stem cell factor [43] and vascular endothelial growth factor (VEGF) [44] can directly induce the expansion of MDSCs.

VEGF is secreted by macrophages [45], DCs [46], T-cells [47] and renal tubular epithelial cells [48] and is often found after injury or in tumour-related diseases. It is also an important factor for differentiation of haematopoietic progenitor cells [49, 50]. VEGF suppresses DC generation and activation in favour of increased production of immature myeloid progenitor cells [49, 50]. Furthermore, recent studies have shown that inhibiting VEGF interaction with its receptors can prevent infiltration of MDSCs and regulatory T-cells (T-regs) while simultaneously increasing DC differentiation [51].

G-CSF often plays a vital role in neutrophil generation and mobilisation in inflammatory conditions [41]. However G-CSF have also been shown to induce G-MDSC proliferation and accumulation in the presence of tumour [52-54]. M-CSF and stem cell factor are generally found secreted in tumour microenvironment. M-CSF were found to be secreted in conjunction with IL-6 by in human renal cell carcinoma cell line, which have prevented DC generation from hematopoietic stem cells (HSCs) and triggered their commitment to monocytic cells [42]. Stem cell factor have been shown to be secreted by murine and human tumour cell lines, and tumour-

bearing mice, and blockade of stem cell factor function have greatly reduced MDSC expansion and enhanced tumour regression [43].

PGE$_2$ is also often associated with inflammatory responses and tumour-related diseases [32, 51, 55]. Tumour cells were found to express PGE$_2$, which can directly interact with HSCs through PGE$_2$ receptors to induce proliferation into MDSCs, thus promoting tumour survival [32, 51, 55]. PGE$_2$ can also induce indirect MDSC proliferation and accumulation by inducing secretion of factors such as VEGF, cyclooxygenase 2 (COX2) and IL-6 [32].

In addition to these growth factors, MDSCs can also be exposed to factors such as IFN-γ to induce activation. IFN-γ is secreted by a number of different immune cells to influence T-cell and MDSC functions [12, 13]. When exposed to IFN-γ, MDSCs express arginase-I and iNOS, which in turn prevent T-cell activation and promote T-cell apoptosis [12, 13]. Several studies have also shown that other cytokines such as IL-1ß, IL-4, IL-6, IL-10 and TGF-ß can also play a role in promoting MDSC generation and may enhance their suppressive function [20, 56, 57].

4. MECHANISMS OF MDSC-MEDIATED IMMUNE SUPPRESSION

MDSC-induced suppression requires cell-to-cell contact due to interaction of cell surface markers and secretion of transitory mediators [30, 58, 59]. The main suppressive activity of MDSCs is associated with secretion of arginase-I, iNOS and ROS [12, 60] (Figure 2). iNOS breaks down L-arginine into nitric oxide (NO) while arginase-I breaks down L-arginine into urea and L-ornithine. Depleting L-arginine prevents CD3 generation on T-cells [61]. NO inhibits effector T-cell activation through Janus-Kinase (JAK) 3 and signal transducer and activator of transcription (STAT) 5 pathways and also abrogates MHCII molecule expression on antigen presenting cells (APCs) [60, 62]. MDSCs can also induce effector T-cell apoptosis [12, 13, 60, 62].

ROS expression plays an important role in MDSC-mediated suppression. Its production by MDSCs can be induced in response to T-cell interaction or by exposure to cytokines such as TGF-ß IL-6, IL-10 and GM-CSF [57]. Hydrogen peroxide, a common form of ROS, prevents cytokine secretion by T-cells and induces T-cell apoptosis [63]. Earlier studies have also shown that IFN-γ produced by immune cells at the site of injury can induce ROS and NO production in MDSCs [64].

Peroxynitrite is produced by a reaction of NO with hydrogen peroxide and is one of the most damaging oxidants in the body [65]. Secretion of peroxynitrite has been observed at sites of inflammation and where MDSCs and immune cells accumulate [66]. Different types of cancers have also been shown to induce high levels of peroxynitrite in their microenvironment, which renders T-cells unresponsive to antigen-specific stimulation [67, 68].

Recent findings have shown that MDSCs also secrete S100 calcium binding protein A8 and A9 (S100A8 and S100A9) [36]. Expression of these functional proteins is often associated with inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, cystic fibrosis and psoriasis [69-73]. However, STAT3-dependent upregulation of S100A9 can be initiated by tumour-derived factors, preventing DC differentiation while promoting MDSC accumulation [74]. S100A8 and S100A9 secreted within a tumour microenvironment can promote MDSC migration to tumour sites by inducing an autocrine pathway through activation of carboxylated N-glycan receptors on these cells [75].

Furthermore, MDSCs can induce T-reg expansion in the presence of IFN-γ and IL-10, disrupt innate immunity by interacting with macrophages, NK cells and NK T-cells, thus enhance tumour progression [76].

Figure 2. Different mechanisms employed by MDSCs to mediate immunosuppression.

5. MDSCs IN DISEASES

The importance of the suppressive roles of MDSCs was initially characterised in studies involving cancer patients and cancer-bearing mice [66, 77]. However, recent studies have shown that MDSCs are also involved in other pathological settings.

5.1 MDSCs in cancer

Most patients with advanced cancer are immunosuppressed, and the cause of immunosuppression can be instigated by a variety of immune cells such as tumour-associated macrophages, suppressive type II NK T-cells, T-regs and MDSCs, which in turn can promote tumour survival and expansion [11]. Although a variety of immunosuppressive cell types can be present in a tumour microenvironment, it was noted that MDSCs are consistently found in most cancer patients [78]. In fact, MDSCs were increased up to tenfold in the blood of cancer patients when compared to healthy individuals [78]. Similarly, in murine tumour models, 20-40% of nucleated splenocytes (in contrast to 2-4% in healthy mice) and 30–70% of tumour-infiltrating leukocytes were found to be MDSCs [79-81]. Accumulation and activation of MDSCs has been further associated with immunosuppression by abrogating effector T-cell response and mediating T-reg responses [21]. Collectively, these findings suggest that the suppressive effects of MDSCs play a major role in tumour survival by assisting tumour to escape immunosurveillance and recruiting other regulatory cells such as T-regs. While studies have shown that cancer progression can be retarded or reversed with the removal of MDSCs [82, 83], more studies are needed in procuring an effective way of mitigating their suppressive effects in cancer.

5.2 MDSCs in other pathological conditions

Although most knowledge on MDSCs and their role in the immune system has been gained from studies in cancer, recent findings suggest that these cells are also involved in pathogenic infections [10], sepsis [7], autoimmune diseases [9] and transplantation [84]. For example, the inflammatory heart infiltrate from mice infected with *Trypanosoma cruzi* consisted mainly of $CD11b^+$ $Ly6G^-$ $Ly6C^+$ MDSCs [85]. These cells exhibited a monocytic phenotype and expressed arginase-1 and iNOS, both of which can suppress T-cell proliferation and prevented clearance of the parasite. In another study, looking at *Leishmania major* infection, NO expressing $CD11b^+$ $Gr-1^+$ ($Ly6C^{hi}$) MDSCs circulated within the blood and infiltrated skin lesions [10]. These cells could suppress effector T-cell proliferation through NO expression. However, upon treatment with IFN-γ and IL-4, they could eliminate the parasites in a NO-dependent manner. A similar expansion of MDSCs was also seen in Hepatitis C virus (HCV) infections in humans, where T-cell proliferation was suppressed through a ROS-mediated mechanism [86].

During polymicrobial sepsis, $CD11b^+$ $Gr-1^+$ MDSCs increased dramatically in the spleen, lymph nodes and bone marrow and remained elevated for an extended period of time [7]. These cells supressed IFN-γ secretion by CD8 T-cells, skewing the immune response from a Th1 to a Th2 profile.

Immunosuppression is often depicted as the bane of the immune system. However, it can be beneficial in the context of autoimmune diseases and in transplantation settings. In autoimmune diseases such as the inflammatory bowel disease (IBD) mouse model, a substantial population of $CD11b^+$ $Gr-1^+$ MDSCs was detected in the spleen and the intestine upon adoptive transfer of haemagglutinin (HA)-specific $CD8^+$ T cells. These MDSCs released NO-synthase-2 and arginase-1 to prevent T-cell proliferation and induced T-cell apoptosis [9]. MDSCs also prevent the onset of autoimmune diabetes by inducing antigen-specific T-reg

expansion and suppressing effector T-cell proliferation through an MHCII-dependent processes in diabetic mouse models [87]. Similarly, in transplantation settings, investigators have made use of the suppressive effects of MDSCs. In a recent study by Chou and colleagues, MDSCs mixed with islet allografts were transplanted into diabetic mice [88]. This effectively protected the islet, by preventing a CD8 T-cell response and inducing expansion of T-regs within the graft. This effect was also seen in other cases, where MDSCs were used to prolong graft survival by inducing allograft tolerance [84, 89, 90]. Collating these recent findings, it is clear that the immune regulatory properties of MDSCs are playing an important role in many pathological conditions, albeit their properties are detrimental in cancer and pathogenic infections. This evidence also suggests that not only is it important to remove MDSCs in diseases such as cancer and pathological infections, it is also crucial to learn how to generate these cells so that their properties can be exploited for future treatments for autoimmune diseases and transplantation settings.

6. CONCLUSION

Recent studies have been able to distinguish inflammatory neutrophils, monocytes and DCs from immunosuppressive MDSCs, a heterogeneous population of myeloid cells with distinctly different function. The increased interest in the elusive MDSCs over the recent years has shed new light on how immunity is regulated in different pathological conditions, particularly in animal models. More in-depth research is required to clearly define MDSCs in humans. Also, little is known about the molecular mechanisms which trigger the generation and expansion of these cells from the progenitor cell populations. Deeper understanding of these cells and their function within the immune system is likely to open opportunities for new therapeutic interventions in cancer and autoimmune diseases.

REFERENCES

[1]Dolcetti, L.; Peranzoni, E.; Ugel, S.; Marigo, I.; Fernandez Gomez, A.; Mesa, C.; Geilich, M.; Winkels, G.; Traggiai, E.; Casati, A.; Grassi, F.; Bronte, V., Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. *Eur J Immunol,* 2010, *40,* (1), 22-35.
[2] Geissmann, F.; Jung, S.; Littman, D.R., Blood monocytes consist of two principal subsets with distinct migratory properties. *Immunity,* 2003, *19,* (1), 71-82.
[3] Rossner, S.; Voigtlander, C.; Wiethe, C.; Hanig, J.; Seifarth, C.; Lutz, M.B., Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. *Eur J Immunol,* 2005, *35,* (12), 3533-3544.
[4] Angulo, I.; de las Heras, F.G.; Garcia-Bustos, J.F.; Gargallo, D.; Munoz-Fernandez, M.A.; Fresno, M., Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. *Blood,* 2000, *95,* (1), 212-220.
[5] Brys, L.; Beschin, A.; Raes, G.; Ghassabeh, G.H.; Noel, W.; Brandt, J.; Brombacher, F.; De Baetselier, P., Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative

capacity of alternatively activated myeloid cells elicited during helminth infection. *J Immunol,* 2005, *174,* (10), 6095-6104.

[6] De Santo, C.; Salio, M.; Masri, S.H.; Lee, L.Y.; Dong, T.; Speak, A.O.; Porubsky, S.; Booth, S.; Veerapen, N.; Besra, G.S.; Grone, H.J.; Platt, F.M.; Zambon, M.; Cerundolo, V., Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. *J Clin Invest,* 2008, *118,* (12), 4036-4048.

[7] Delano, M.J.; Scumpia, P.O.; Weinstein, J.S.; Coco, D.; Nagaraj, S.; Kelly-Scumpia, K.M.; O'Malley, K.A.; Wynn, J.L.; Antonenko, S.; Al-Quran, S.Z.; Swan, R.; Chung, C.S.; Atkinson, M.A.; Ramphal, R.; Gabrilovich, D.I.; Reeves, W.H.; Ayala, A.; Phillips, J.; Laface, D.; Heyworth, P.G.; Clare-Salzler, M.; Moldawer, L.L., MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. *J Exp Med,* 2007, *204,* (6), 1463-1474.

[8] Makarenkova, V.P.; Bansal, V.; Matta, B.M.; Perez, L.A.; Ochoa, J.B., CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. *J Immunol,* 2006, *176,* (4), 2085-2094.

[9] Haile, L.A.; von Wasielewski, R.; Gamrekelashvili, J.; Kruger, C.; Bachmann, O.; Westendorf, A.M.; Buer, J.; Liblau, R.; Manns, M.P.; Korangy, F.; Greten, T.F., Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. *Gastroenterology,* 2008, *135,* (3), 871-881, 881 e871-875.

[10] Pereira, W.F.; Ribeiro-Gomes, F.L.; Guillermo, L.V.; Vellozo, N.S.; Montalvao, F.; Dosreis, G.A.; Lopes, M.F., Myeloid-derived suppressor cells help protective immunity to Leishmania major infection despite suppressed T cell responses. *J Leukoc Biol,* 2011, *90,* (6), 1191-1197.

[11] Solinas, G.; Germano, G.; Mantovani, A.; Allavena, P., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. *J Leukoc Biol,* 2009, *86,* (5), 1065-1073.

[12] Bronte, V.; Serafini, P.; Mazzoni, A.; Segal, D.M.; Zanovello, P., L-arginine metabolism in myeloid cells controls T-lymphocyte functions. *Trends Immunol,* 2003, *24,* (6), 302-306.

[13] Rivoltini, L.; Carrabba, M.; Huber, V.; Castelli, C.; Novellino, L.; Dalerba, P.; Mortarini, R.; Arancia, G.; Anichini, A.; Fais, S.; Parmiani, G., Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. *Immunol Rev,* 2002, *188,* 97-113.

[14] Zhao, F.; Obermann, S.; von Wasielewski, R.; Haile, L.; Manns, M.P.; Korangy, F.; Greten, T.F., Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. *Immunology,* 2009, *128,* (1), 141-149.

[15] Ilkovitch, D.; Lopez, D.M., The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. *Cancer Res,* 2009, *69,* (13), 5514-5521.

[16] Kusmartsev, S.; Nefedova, Y.; Yoder, D.; Gabrilovich, D.I., Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. *J Immunol,* 2004, *172,* (2), 989-999.

[17] Youn, J.I.; Nagaraj, S.; Collazo, M.; Gabrilovich, D.I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. *J Immunol,* 2008, *181,* (8), 5791-5802.

[18] Huang, B.; Lei, Z.; Zhao, J.; Gong, W.; Liu, J.; Chen, Z.; Liu, Y.; Li, D.; Yuan, Y.; Zhang, G.M.; Feng, Z.H., CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. *Cancer letters,* 2007, *252,* (1), 86-92.

[19] Movahedi, K.; Guilliams, M.; Van den Bossche, J.; Van den Bergh, R.; Gysemans, C.; Beschin, A.; De Baetselier, P.; Van Ginderachter, J.A., Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. *Blood,* 2008, *111,* (8), 4233-4244.

[20] Gallina, G.; Dolcetti, L.; Serafini, P.; De Santo, C.; Marigo, I.; Colombo, M.P.; Basso, G.; Brombacher, F.; Borrello, I.; Zanovello, P.; Bicciato, S.; Bronte, V., Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. *J Clin Invest,* 2006, *116,* (10), 2777-2790.

[21]   Huang, B.; Pan, P.Y.; Li, Q.; Sato, A.I.; Levy, D.E.; Bromberg, J.; Divino, C.M.; Chen, S.H., Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. *Cancer Res,* **2006**, *66*, (2), 1123-1131.

[22]   Serafini, P.; Borrello, I.; Bronte, V., Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. *Semin Cancer Biol,* **2006**, *16*, (1), 53-65.

[23]   Lechner, M.G.; Megiel, C.; Russell, S.M.; Bingham, B.; Arger, N.; Woo, T.; Epstein, A.L., Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. *Journal of translational medicine,* **2011**, *9*, 90.

[24]   Brandau, S.; Trellakis, S.; Bruderek, K.; Schmaltz, D.; Steller, G.; Elian, M.; Suttmann, H.; Schenck, M.; Welling, J.; Zabel, P.; Lang, S., Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. *J Leukoc Biol,* **2011**, *89*, (2), 311-317.

[25]   Vuk-Pavlovic, S.; Bulur, P.A.; Lin, Y.; Qin, R.; Szumlanski, C.L.; Zhao, X.; Dietz, A.B., Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. *The Prostate,* **2010**, *70*, (4), 443-455.

[26]   Liu, C.Y.; Wang, Y.M.; Wang, C.L.; Feng, P.H.; Ko, H.W.; Liu, Y.H.; Wu, Y.C.; Chu, Y.; Chung, F.T.; Kuo, C.H.; Lee, K.Y.; Lin, S.M.; Lin, H.C.; Wang, C.H.; Yu, C.T.; Kuo, H.P., Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. *J Cancer Res Clin Oncol,* **2010**, *136*, (1), 35-45.

[27]   Poschke, I.; Mougiakakos, D.; Hansson, J.; Masucci, G.V.; Kiessling, R., Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. *Cancer Res,* **2010**, *70*, (11), 4335-4345.

[28]   Brimnes, M.K.; Vangsted, A.J.; Knudsen, L.M.; Gimsing, P.; Gang, A.O.; Johnsen, H.E.; Svane, I.M., Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. *Scand J Immunol,* **2010**, *72*, (6), 540-547.

[29]   Zea, A.H.; Rodriguez, P.C.; Atkins, M.B.; Hernandez, C.; Signoretti, S.; Zabaleta, J.; McDermott, D.; Quiceno, D.; Youmans, A.; O'Neill, A.; Mier, J.; Ochoa, A.C., Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. *Cancer Res,* **2005**, *65*, (8), 3044-3048.

[30]   Rodriguez, P.C.; Ernstoff, M.S.; Hernandez, C.; Atkins, M.; Zabaleta, J.; Sierra, R.; Ochoa, A.C., Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. *Cancer Res,* **2009**, *69*, (4), 1553-1560.

[31]   Filipazzi, P.; Valenti, R.; Huber, V.; Pilla, L.; Canese, P.; Iero, M.; Castelli, C.; Mariani, L.; Parmiani, G.; Rivoltini, L., Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology,* **2007**, *25*, (18), 2546-2553.

[32]   Xiang, X.; Poliakov, A.; Liu, C.; Liu, Y.; Deng, Z.B.; Wang, J.; Cheng, Z.; Shah, S.V.; Wang, G.J.; Zhang, L.; Grizzle, W.E.; Mobley, J.; Zhang, H.G., Induction of myeloid-derived suppressor cells by tumor exosomes. *Int J Cancer,* **2009**, *124*, (11), 2621-2633.

[33]   Kusmartsev, S.; Su, Z.; Heiser, A.; Dannull, J.; Eruslanov, E.; Kubler, H.; Yancey, D.; Dahm, P.; Vieweg, J., Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research,* **2008**, *14*, (24), 8270-8278.

[34]   Mandruzzato, S.; Solito, S.; Falisi, E.; Francescato, S.; Chiarion-Sileni, V.; Mocellin, S.; Zanon, A.; Rossi, C.R.; Nitti, D.; Bronte, V.; Zanovello, P., IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. *J Immunol,* **2009**, *182*, (10), 6562-6568.

[35]   Luyckx, A.; Schouppe, E.; Rutgeerts, O.; Lenaerts, C.; Fevery, S.; Devos, T.; Dierickx, D.; Waer, M.; Van Ginderachter, J.A.; Billiau, A.D., G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. *Clin Immunol,* **2012**.

[36]   Zhao, F.; Hoechst, B.; Duffy, A.; Gamrekelashvili, J.; Fioravanti, S.; Manns, M.P.; Greten, T.F.; Korangy, F., S100A9 a new marker for monocytic human myeloid derived suppressor cells. *Immunology,* **2012**.

[37]   Lutz, M.B.; Suri, R.M.; Niimi, M.; Ogilvie, A.L.; Kukutsch, N.A.; Rossner, S.; Schuler, G.; Austyn, J.M., Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. *Eur J Immunol,* **2000**, *30*, (7), 1813-1822.

[38]   Abdalla, A.O.; Kiaii, S.; Hansson, L.; Rossmann, E.D.; Jeddi-Tehrani, M.; Shokri, F.; Osterborg, A.; Mellstedt, H.; Rabbani, H., Kinetics of cytokine gene expression in human CD4+ and CD8+ T-lymphocyte subsets using quantitative real-time PCR. *Scand J Immunol,* **2003**, *58*, (6), 601-606.

[39]   de Saint-Vis, B.; Fugier-Vivier, I.; Massacrier, C.; Gaillard, C.; Vanbervliet, B.; Ait-Yahia, S.; Banchereau, J.; Liu, Y.J.; Lebecque, S.; Caux, C., The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. *J Immunol,* **1998**, *160*, (4), 1666-1676.

[40]   Morris, M.A.; Ley, K., Trafficking of natural killer cells. *Curr Mol Med,* **2004**, *4*, (4), 431-438.

[41]   Croker, B.A.; Metcalf, D.; Robb, L.; Wei, W.; Mifsud, S.; DiRago, L.; Cluse, L.A.; Sutherland, K.D.; Hartley, L.; Williams, E.; Zhang, J.G.; Hilton, D.J.; Nicola, N.A.; Alexander, W.S.; Roberts, A.W., SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. *Immunity,* **2004**, *20*, (2), 153-165.

[42]   Menetrier-Caux, C.; Montmain, G.; Dieu, M.C.; Bain, C.; Favrot, M.C.; Caux, C.; Blay, J.Y., Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. *Blood,* **1998**, *92*, (12), 4778-4791.

[43]   Pan, P.Y.; Wang, G.X.; Yin, B.; Ozao, J.; Ku, T.; Divino, C.M.; Chen, S.H., Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. *Blood,* **2008**, *111*, (1), 219-228.

[44]   Nakamura, Y.; Yasuoka, H.; Tsujimoto, M.; Yoshidome, K.; Nakahara, M.; Nakao, K.; Nakamura, M.; Kakudo, K., Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. *Clinical cancer research : an official journal of the American Association for Cancer Research,* **2006**, *12*, (4), 1201-1207.

[45]   Kataru, R.P.; Jung, K.; Jang, C.; Yang, H.; Schwendener, R.A.; Baik, J.E.; Han, S.H.; Alitalo, K.; Koh, G.Y., Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. *Blood,* **2009**, *113*, (22), 5650-5659.

[46]   Nam, E.H.; Park, S.R.; Kim, P.H., TGF-beta1 induces mouse dendritic cells to express VEGF and its receptor (Flt-1) under hypoxic conditions. *Experimental & molecular medicine,* **2010**, *42*, (9), 606-613.

[47]   Marek, N.; Mysliwiec, M.; Raczynska, K.; Zorena, K.; Mysliwska, J.; Trzonkowski, P., Increased spontaneous production of VEGF by CD4+ T cells in type 1 diabetes. *Clin Immunol,* **2010**, *137*, (2), 261-270.

[48]   Rudnicki, M.; Perco, P.; Enrich, J.; Eder, S.; Heininger, D.; Bernthaler, A.; Wiesinger, M.; Sarkozi, R.; Noppert, S.J.; Schramek, H.; Mayer, B.; Oberbauer, R.; Mayer, G., Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. *Laboratory investigation; a journal of technical methods and pathology,* **2009**, *89*, (3), 337-346.

[49]   Gabrilovich, D.; Ishida, T.; Oyama, T.; Ran, S.; Kravtsov, V.; Nadaf, S.; Carbone, D.P., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. *Blood,* **1998**, *92*, (11), 4150-4166.

[50]   Gabrilovich, D.I.; Chen, H.L.; Girgis, K.R.; Cunningham, H.T.; Meny, G.M.; Nadaf, S.; Kavanaugh, D.; Carbone, D.P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. *Nat Med,* **1996**, *2*, (10), 1096-1103.

[51]   Roland, C.L.; Lynn, K.D.; Toombs, J.E.; Dineen, S.P.; Udugamasooriya, D.G.; Brekken, R.A., Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. *PLoS One,* **2009**, *4,* (11), e7669.

[52]   Nefedova, Y.; Nagaraj, S.; Rosenbauer, A.; Muro-Cacho, C.; Sebti, S.M.; Gabrilovich, D.I., Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. *Cancer Res,* **2005**, *65,* (20), 9525-9535.

[53]   Nefedova, Y.; Huang, M.; Kusmartsev, S.; Bhattacharya, R.; Cheng, P.; Salup, R.; Jove, R.; Gabrilovich, D., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. *J Immunol,* **2004**, *172,* (1), 464-474.

[54]   Kortylewski, M.; Kujawski, M.; Wang, T.; Wei, S.; Zhang, S.; Pilon-Thomas, S.; Niu, G.; Kay, H.; Mule, J.; Kerr, W.G.; Jove, R.; Pardoll, D.; Yu, H., Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. *Nat Med,* **2005**, *11,* (12), 1314-1321.

[55]   Sinha, P.; Clements, V.K.; Fulton, A.M.; Ostrand-Rosenberg, S., Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. *Cancer Res,* **2007**, *67,* (9), 4507-4513.

[56]   Song, X.; Krelin, Y.; Dvorkin, T.; Bjorkdahl, O.; Segal, S.; Dinarello, C.A.; Voronov, E.; Apte, R.N., CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. *J Immunol,* **2005**, *175,* (12), 8200-8208.

[57]   Sauer, H.; Wartenberg, M.; Hescheler, J., Reactive oxygen species as intracellular messengers during cell growth and differentiation. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,* **2001**, *11,* (4), 173-186.

[58]   Yang, R.; Cai, Z.; Zhang, Y.; Yutzy, W.H.t.; Roby, K.F.; Roden, R.B., CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. *Cancer Res,* **2006**, *66,* (13), 6807-6815.

[59]   Ochoa, A.C.; Zea, A.H.; Hernandez, C.; Rodriguez, P.C., Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research,* **2007**, *13,* (2 Pt 2), 721s-726s.

[60]   Bingisser, R.M.; Tilbrook, P.A.; Holt, P.G.; Kees, U.R., Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. *J Immunol,* **1998**, *160,* (12), 5729-5734.

[61]   Rodriguez, P.C.; Zea, A.H.; Culotta, K.S.; Zabaleta, J.; Ochoa, J.B.; Ochoa, A.C., Regulation of T cell receptor CD3zeta chain expression by L-arginine. *The Journal of biological chemistry,* **2002**, *277,* (24), 21123-21129.

[62]   Harari, O.; Liao, J.K., Inhibition of MHC II gene transcription by nitric oxide and antioxidants. *Curr Pharm Des,* **2004**, *10,* (8), 893-898.

[63]   Malmberg, K.J.; Arulampalam, V.; Ichihara, F.; Petersson, M.; Seki, K.; Andersson, T.; Lenkei, R.; Masucci, G.; Pettersson, S.; Kiessling, R., Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. *J Immunol,* **2001**, *167,* (5), 2595-2601.

[64]   Mazzoni, A.; Bronte, V.; Visintin, A.; Spitzer, J.H.; Apolloni, E.; Serafini, P.; Zanovello, P.; Segal, D.M., Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. *J Immunol,* **2002**, *168,* (2), 689-695.

[65]   Pacher, P.; Beckman, J.S.; Liaudet, L., Nitric oxide and peroxynitrite in health and disease. *Physiological reviews,* **2007**, *87,* (1), 315-424.

[66]   Maeda, H.; Akaike, T., Nitric oxide and oxygen radicals in infection, inflammation, and cancer. *Biochemistry. Biokhimiia,* **1998**, *63,* (7), 854-865.

[67]   Nagaraj, S.; Youn, J.I.; Weber, H.; Iclozan, C.; Lu, L.; Cotter, M.J.; Meyer, C.; Becerra, C.R.; Fishman, M.; Antonia, S.; Sporn, M.B.; Liby, K.T.; Rawal, B.; Lee, J.H.; Gabrilovich, D.I., Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research,* **2010**, *16,* (6), 1812-1823.

[68]   Nagaraj, S.; Gupta, K.; Pisarev, V.; Kinarsky, L.; Sherman, S.; Kang, L.; Herber, D.L.; Schneck, J.; Gabrilovich, D.I., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. *Nat Med,* **2007**, *13,* (7), 828-835.

[69]   Roth, J.; Goebeler, M.; Sorg, C., S100A8 and S100A9 in inflammatory diseases. *Lancet,* **2001**, *357,* (9261), 1041.

[70]   Tirkos, S.; Newbigging, S.; Nguyen, V.; Keet, M.; Ackerley, C.; Kent, G.; Rozmahel, R.F., Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator. *Respiratory research,* **2006**, *7,* 51.

[71]   Nukui, T.; Ehama, R.; Sakaguchi, M.; Sonegawa, H.; Katagiri, C.; Hibino, T.; Huh, N.H., S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes. *Journal of cellular biochemistry,* **2008**, *104,* (2), 453-464.

[72]   Leach, S.T.; Yang, Z.; Messina, I.; Song, C.; Geczy, C.L.; Cunningham, A.M.; Day, A.S., Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. *Scandinavian journal of gastroenterology,* **2007**, *42,* (11), 1321-1331.

[73]   Bogumil, T.; Rieckmann, P.; Kubuschok, B.; Felgenhauer, K.; Bruck, W., Serum levels of macrophage-derived protein MRP-8/14 are elevated in active multiple sclerosis. *Neuroscience letters,* **1998**, *247,* (2-3), 195-197.

[74]   Cheng, P.; Corzo, C.A.; Luetteke, N.; Yu, B.; Nagaraj, S.; Bui, M.M.; Ortiz, M.; Nacken, W.; Sorg, C.; Vogl, T.; Roth, J.; Gabrilovich, D.I., Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. *J Exp Med,* **2008**, *205,* (10), 2235-2249.

[75]   Sinha, P.; Okoro, C.; Foell, D.; Freeze, H.H.; Ostrand-Rosenberg, S.; Srikrishna, G., Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. *J Immunol,* **2008**, *181,* (7), 4666-4675.

[76]   Sinha, P.; Clements, V.K.; Ostrand-Rosenberg, S., Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. *Cancer Res,* **2005**, *65,* (24), 11743-11751.

[77]   Buessow, S.C.; Paul, R.D.; Lopez, D.M., Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. *Journal of the National Cancer Institute,* **1984**, *73,* (1), 249-255.

[78]   Greten, T.F.; Manns, M.P.; Korangy, F., Myeloid derived suppressor cells in human diseases. *International immunopharmacology,* **2011**, *11,* (7), 802-807.

[79]   Lees, J.R.; Azimzadeh, A.M.; Bromberg, J.S., Myeloid derived suppressor cells in transplantation. *Curr Opin Immunol,* **2011**, *23,* (5), 692-697.

[80]   Ueha, S.; Shand, F.H.; Matsushima, K., Myeloid cell population dynamics in healthy and tumor-bearing mice. *International immunopharmacology,* **2011**, *11,* (7), 783-788.

[81]   Sawanobori, Y.; Ueha, S.; Kurachi, M.; Shimaoka, T.; Talmadge, J.E.; Abe, J.; Shono, Y.; Kitabatake, M.; Kakimi, K.; Mukaida, N.; Matsushima, K., Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. *Blood,* **2008**, *111,* (12), 5457-5466.

[82]   Raychaudhuri, B.; Rayman, P.; Ireland, J.; Ko, J.; Rini, B.; Borden, E.C.; Garcia, J.; Vogelbaum, M.A.; Finke, J., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. *Neuro-oncology,* **2011**, *13,* (6), 591-599.

[83]   Srivastava, M.K.; Zhu, L.; Harris-White, M.; Kar, U.K.; Huang, M.; Johnson, M.F.; Lee, J.M.; Elashoff, D.; Strieter, R.; Dubinett, S.; Sharma, S., Correction: Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer. *PLoS One,* **2012**, *7,* (10).

[84]   De Wilde, V.; Van Rompaey, N.; Hill, M.; Lebrun, J.F.; Lemaitre, P.; Lhomme, F.; Kubjak, C.; Vokaer, B.; Oldenhove, G.; Charbonnier, L.M.; Cuturi, M.C.; Goldman, M.; Le Moine, A., Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, **2009**, *9*, (9), 2034-2047.

[85] Cuervo, H.; Guerrero, N.A.; Carbajosa, S.; Beschin, A.; De Baetselier, P.; Girones, N.; Fresno, M., Myeloid-derived suppressor cells infiltrate the heart in acute Trypanosoma cruzi infection. *J Immunol,* **2011**, *187*, (5), 2656-2665.

[86] Tacke, R.S.; Lee, H.C.; Goh, C.; Courtney, J.; Polyak, S.J.; Rosen, H.R.; Hahn, Y.S., Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. *Hepatology,* **2012**, *55*, (2), 10.

[87] Yin, B.; Ma, G.; Yen, C.Y.; Zhou, Z.; Wang, G.X.; Divino, C.M.; Casares, S.; Chen, S.H.; Yang, W.C.; Pan, P.Y., Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. *J Immunol,* **2010**, *185*, (10), 5828-5834.

[88] Chou, H.S.; Hsieh, C.C.; Charles, R.; Wang, L.; Wagner, T.; Fung, J.J.; Qian, S.; Lu, L.L., Myeloid-derived suppressor cells protect islet transplants by b7-h1 mediated enhancement of T regulatory cells. *Transplantation,* **2012**, *93*, (3), 272-282.

[89] Zhang, W.; Liang, S.; Wu, J.; Horuzsko, A., Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. *Transplantation,* **2008**, *86*, (8), 1125-1134.

[90] Shen, L.; Jin, Y.; Freeman, G.J.; Sharpe, A.H.; Dana, M.R., The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. *J Immunol,* **2007**, *179*, (6), 3672-3679.